Establishing long-term survival and cure in young patients with Ewing's sarcoma

Weston, Claire; Douglas, C; Craft, A W; Lewis, Ian; Machin, David

doi:10.1038/sj.bjc.6601955

Cited by 17 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mixture survival models have been applied to colon cancer data collected in Finland 1953–1992 6 and Weston et al . have described the long‐term survival following diagnoses of Ewing's sarcoma, quantifying the cure in young patients 37…”

Section: Discussionmentioning

confidence: 99%

Proportion cured models applied to 23 cancer sites in Norway

Cvancarova

Aagnes

Fosså

et al. 2012

Intl Journal of Cancer

View full text Add to dashboard Cite

Statistical cure is reached when a group of patients has the same mortality as cancer-free individuals. Cure models predict the cured proportion and the median survival of fatal cases. Cure models have seldom been applied and tested systematically across all major cancer sites. Incidence and follow-up data on 23 cancer sites recorded at the Cancer Registry of Norway 1963-2007 were obtained. Mixture cure models were fitted to obtain trends and up-to-date estimates (based on period approach) assuming cured and uncured groups exist. The model converged for cancers of the mouth and pharynx, oesophagus, stomach, colon, rectum, liver, gallbladder, pancreas, lung and trachea, ovary, kidney, bladder, CNS, non-Hodgkin lymphoma (only for males) and leukemia. The proportion of cured patients increased 1963-2002 for both sexes, with the largest changes (in percent) seen for leukemia (46.4 and 46.7) and CNS (35.9, 42.0), males given first. Median survival time for the uncured cases increased for colon and rectal cancer, and there was a three-fold increase in median survival time for patients with fatal ovarian cancers. Cancers of bladder and CNS had the highest up-to-date proportion cured (in percent), 67.4 and 64.0, respectively, pancreas and liver were amongst the lowest (5.7 and 9.9, respectively). Cure models are useful when monitoring progress in cancer care, but must be applied and interpreted with caution. The absolute estimates of the cure proportion are speculative and should not be calculated where cure is not medically anticipated.Increasingly, cancer patients as a group-at least those diagnosed with treatable cancers in higher-resource settings-survive their initial diagnosis and remain tumor-free for longer periods than has been observed in previous decades 1 This favorable trend in cancer care has warranted the development of novel statistical tools to monitor the effectiveness of early detection strategies and the quality of clinical care and cancer management, including procedures to estimate the proportion of cured patients alongside the median survival of fatal cases using so-called cure models.2,3 From the offset, the inherent differences between the concepts of clinical versus statistical cure need to be understood. Statistical cure is applicable to observations examined at the group level and is distinct from medical cure of the individual, as commonly determined in a clinical setting on the basis of lack of specific symptoms of the patients, achieved, for example, when all cancerous cells in the body have been persistently eradicated. 4 The models, when applied to population-based cancer survival data, serve to provide estimates of the proportion of statistically cured individuals, that is, a group of cancer patients whom, after a certain time period, are observed to have little or no excess mortality relative to the general population.Such models have been applied to aid clinical interpretation of survival trends for specific cancer sites in one or more populations. A recent EUROCARE study presented es...

show abstract

Section: Discussionmentioning

confidence: 99%

Proportion cured models applied to 23 cancer sites in Norway

Cvancarova

Aagnes

Fosså

et al. 2012

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Second, the five year survival rate of disease increased in the past three decades from 42% to 58% and then to more than 60% worldwide (Oberlin et al, 2001;Haeusler et al, 2010). Increasing survival continued until some specialists suggested that 'cure' is possible for patients with Ewing's sarcoma (Weston et al, 2004). Third the five year survival rates in recurrent disease is only 13% (Leavey et al, 2008).…”

Section: Discussionmentioning

confidence: 99%

Survival of Patients with Ewing's Sarcoma in Yazd-Iran

Akhavan

Binesh²,

Shamshiri³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The Ewing's sarcoma family is a group of small round cell tumors which accounts for 10-15% of all primary bone neoplasms. The aim of this study was to evaluate the survival of Ewing's sarcoma patients in our province and to determine of influencing factors. Materials and Methods: All patients with documented Ewing's sarcoma/ primitive neuroectodermal tumor(PNET) family pathology were enrolled in this study during a period of eight years. For all of them local and systemic therapy were carried out. Overall and event free survival and prognostic factors were evaluated. Results: Thirty two patients were enrolled in the study. The median age was 17.5 years. Twenty (65.2%) were male and 9 (28.1%) were aged 14 years or less. Mean disease free survival was 26.8 (95%CI; 13.8-39.9) months and five year disease free survival was 26%. Mean overall survival was 38.7 months (95%CI; 25.9-50.6) and median overall survival was 24 months. Five year overall survival was 25%. From the variables evaluated , only presence of metastatic disease at presentation (p value=0. 028) and complete response (p value =0. 006) had significant relations to overall survival. Conclusions: Survival of Ewing's sarcoma in our province is disappointing. It seems to be mostly due to less effective treatment. Administration of adequate chemotherapy dosage, resection of tumor with negative margins and precise assessment of irradiation volume may prove helpful.

show abstract

“…The application of the Weibull distribution function approaches multiple clinical applications and it is well established theoretically and practically [9][10][11][12]. It has been used for a long time for survival description in gerontology [13,14] and in oncology [15] as well.…”

Section: Methodsmentioning

confidence: 99%

Oncothermia as Personalized Treatment Option

Szász

Andócs

Meggyesházi

2013

Conference Papers in Medicine

View full text Add to dashboard Cite

Oncothermia is a nanoheating technology personalized for individual status depending on the state, stage, grade, and other personal factors. The guiding line of the treatment keeps the homeostatic control as much effective as possible. One of the crucial points is the surface heat regulation, which has to be carefully done by the electrode systems. The applied stepup heating supports the physiological selection. Recognizing the hysteresis type of SAR-temperature, development of the protocol could be well conducted. Using the Weibull distribution function of the transport processes as well as considering the typical physiological relaxation time of the tissues, special protocols can be developed. It has wide-range applicability for every solid tumor, irrespective of its primary or metastatic form. It could be applied complementary to all the known oncotherapy methods. It is applicable in higher lines of the therapy protocols, even in the refractory and relapsed cases as well.

show abstract

Establishing long-term survival and cure in young patients with Ewing's sarcoma

Cited by 17 publications

References 12 publications

Proportion cured models applied to 23 cancer sites in Norway

Proportion cured models applied to 23 cancer sites in Norway

Survival of Patients with Ewing's Sarcoma in Yazd-Iran

Oncothermia as Personalized Treatment Option

Contact Info

Product

Resources

About